TNFSF11 and osteoporosis: Denosumab, a monoclonal antibody targeting the receptor activator of nuclear factor kappa-B ligand (RANKL), is an effective therapy for osteoporosis in both postmenopausal women and men (Boyle et al., 2003; Kostenuik et al., 2009; Delmas, 2008; Bone et al., 2008; McClung et al., 2006).